Jun 12, 2020
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Jun 12, 2020
EHA25Virtual: Promising Treatment Results with Imetelstat, a Novel Telomerase Inhibitor, in Patients with Lower Risk Myelodysplastic Syndromes
Jun 12, 2020
EHA25Virtual: Pegcetacoplan, a Novel C3 Complement Inhibitor - Beginning of a New Era in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Jun 12, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA(TM) (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 06, 2020
AbbVie Presents Data Showing RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
Jun 04, 2020
New Long-term Data from RINVOQ(TM) (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
Jun 04, 2020
Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune(TM), Designed to Protect Against COVID-19
Jun 04, 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept
Jun 03, 2020
New First-in-Class Phase 3 TREMFYA® (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52
Jun 03, 2020
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
Jun 01, 2020
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Jun 01, 2020
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
Jun 01, 2020
Despite Increased Competition from the Recent Launch of Janssen's Stelara, Takeda's Entyvio Continues to Shine as a Leading Ulcerative Colitis Treatment
May 27, 2020
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
May 27, 2020
Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
May 13, 2020
COVID-19 Prompts New Home Test for Kids with Organ Transplants
Apr 29, 2020
UCB's Cimzia is Making Inroads in the Treatment of Axial Disease, with Significant Uptake in Non-Radiographic Axial Spondyloarthritis and a Positive Treatment Halo in Ankylosing Spondylitis
Apr 24, 2020
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis